Setting

Asia Pacific Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Published: 18 Jan 2020 | Report Code: 10247336 | Pages: 113

Asia Pacific human insulin market will grow by 9.74% annually over forecast years with a total addressable market cap of $66.02 billion for 2020-2026. Highlighted with 37 tables and 56 figures, this 113-page report “Asia Pacific Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify Asia Pacific human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country. Based on product type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Human Insulin Drugs • Human Insulin Delivery Devices Based on product, the Asia Pacific Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand) • Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand) Based on product, the Asia Pacific Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Syringes • Pens (further segmented into Disposable, Reusable, Pen needles) • Pumps • Others Based on application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Type 1 Diabetes • Type 2 Diabetes • Gestational Diabetes and Prediabetes Based on distribution channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players: Astra Zeneca PLC Biocon Eli Lilly Exir Julphar Novo Nordisk AS Pfizer Sanofi Aventis Sedico Wockhardt (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	10
1.2.1 Overview of Market Research Methodology	10
1.2.2 Market Assumption	11
1.2.3 Secondary Data	11
1.2.4 Primary Data	11
1.2.5 Data Filtration and Model Design	12
1.2.6 Market Size/Share Estimation	13
1.2.7 Research Limitations	14
1.3 Executive Summary	15
2 Market Overview and Dynamics	17
2.1 Market Size and Forecast	17
2.2 Major Growth Drivers	18
2.3 Market Restraints and Challenges	21
2.4 Emerging Opportunities and Market Trends	24
2.5 Porter’s Fiver Forces Analysis	27
3 Segmentation of Asia-Pacific Market by Product Type	31
3.1 Market Overview by Product Type	31
3.2 Human Insulin Drugs	33
3.3 Human Insulin Delivery Devices	34
4 Segmentation of Asia-Pacific Human Insulin Drugs Market by Drug Product	35
4.1 Market Overview by Drug Product	35
4.2 Modern Human Insulin	37
4.2.1 Modern Human Insulin by Type	39
4.2.2 Modern Human Insulin by Brand	42
4.3 Traditional Human Insulin	49
4.3.1 Traditional Human Insulin by Type	51
4.3.2 Traditional Human Insulin by Brand	54
5 Segmentation of Asia-Pacific Human Insulin Delivery Devices Market by Device Product	57
5.1 Market Overview by Product	57
5.2 Syringes	59
5.3 Pens	60
5.4 Pumps	61
5.5 Other Devices	63
6 Segmentation of Asia-Pacific Market by Application	64
6.1 Market Overview by Application	64
6.2 Type 1 Diabetes	66
6.3 Type 2 Diabetes	67
6.4 Gestational Diabetes and Prediabetes	68
7 Segmentation of Asia-Pacific Market by Distribution Channel	69
7.1 Market Overview by Distribution Channel	69
7.2 Hospital Pharmacies	71
7.3 Retail Pharmacies	72
7.4 Online Pharmacies	73
8 Asia-Pacific Market 2019-2026 by Country	74
8.1 Overview of Asia-Pacific Market	74
8.2 Japan	77
8.3 China	80
8.4 Australia	82
8.5 India	84
8.6 South Korea	86
8.7 Rest of APAC Region	88
9 Competitive Landscape	90
9.1 Overview of Key Vendors	90
9.2 New Product Launch, Partnership, Investment, and M&A	94
9.3 Company Profiles	96
Astra Zeneca PLC	96
Biocon	98
Eli Lilly	99
Exir	100
Julphar	101
Novo Nordisk AS	102
Pfizer	103
Sanofi Aventis	104
Sedico	105
Wockhardt	106
10 Investing in Asia-Pacific Market: Risk Assessment and Management	107
10.1 Risk Evaluation of Asia-Pacific Market	107
10.2 Critical Success Factors (CSFs)	110
Related Reports and Products	113
List Of Tables

Table 1.  Snapshot of Asia-Pacific Human Insulin Market, 2019-2026	16
Table 2.  Main Product Trends and Market Opportunities in Asia-Pacific Human Insulin Market	24
Table 3. Asia-Pacific Human Insulin Market by Product Type, 2019-2026, $ mn	31
Table 4. Asia-Pacific Human Insulin Drugs Market by Product, 2019-2026, $ mn	35
Table 5. Asia-Pacific Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, $ mn	38
Table 6. Asia-Pacific Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, $ mn	38
Table 7. Asia-Pacific Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, $ mn	50
Table 8. Asia-Pacific Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, $ mn	50
Table 9. Asia-Pacific Human Insulin Delivery Devices Market by Product, 2019-2026, $ mn	57
Table 10. Asia-Pacific Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, $ mn	60
Table 11. Asia-Pacific Human Insulin Market by Application, 2019-2026, $ mn	64
Table 12. Asia-Pacific Human Insulin Market by Distribution Channel, 2019-2026, $ mn	69
Table 13. APAC Human Insulin Market by Country, 2019-2026, $ mn	75
Table 14. Japan Human Insulin Market by Product Type, 2019-2026, $ mn	79
Table 15. Japan Human Insulin Market by Application, 2019-2026, $ mn	79
Table 16. Japan Human Insulin Market by Distribution Channel, 2019-2026, $ mn	79
Table 17. China Human Insulin Market by Product Type, 2019-2026, $ mn	81
Table 18. China Human Insulin Market by Application, 2019-2026, $ mn	81
Table 19. China Human Insulin Market by Distribution Channel, 2019-2026, $ mn	81
Table 20. Australia Human Insulin Market by Product Type, 2019-2026, $ mn	83
Table 21. Australia Human Insulin Market by Application, 2019-2026, $ mn	83
Table 22. Australia Human Insulin Market by Distribution Channel, 2019-2026, $ mn	83
Table 23. India Human Insulin Market by Product Type, 2019-2026, $ mn	85
Table 24. India Human Insulin Market by Application, 2019-2026, $ mn	85
Table 25. India Human Insulin Market by Distribution Channel, 2019-2026, $ mn	85
Table 26. South Korea Human Insulin Market by Product Type, 2019-2026, $ mn	87
Table 27. South Korea Human Insulin Market by Application, 2019-2026, $ mn	87
Table 28. South Korea Human Insulin Market by Distribution Channel, 2019-2026, $ mn	87
Table 29. Human Insulin Market in Rest of APAC by Country, 2019-2026, $ mn	89
Table 30. Asia-Pacific Human Insulin Market by Key Vendor, 2019, $ mn	92
Table 31. Astra Zeneca PLC: Company Snapshot	96
Table 32. Astra Zeneca PLC: Business Segmentation	96
Table 33. Astra Zeneca PLC: Product Portfolio	97
Table 34. Astra Zeneca PLC: Revenue, 2016-2018, $ mn	97
Table 35. Astra Zeneca PLC: Recent Developments	97
Table 36.  Risk Evaluation for Investing in Asia-Pacific Market, 2019-2026	108
Table 37. Critical Success Factors and Key Takeaways	111
List Of Figures

Figure 1.  Research Method Flow Chart	10
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	13
Figure 3. Asia-Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026	15
Figure 4. Asia-Pacific Human Insulin Market, 2019-2026, $ mn	17
Figure 5. Primary Drivers and Impact Factors of Asia-Pacific Human Insulin Market	18
Figure 6. Primary Restraints and Impact Factors of Asia-Pacific Human Insulin Market	21
Figure 7. Porter’s Fiver Forces Analysis of Asia-Pacific Human Insulin Market	27
Figure 8. Breakdown of Asia-Pacific Human Insulin Market by Product Type, 2019-2026, % of Revenue	31
Figure 9. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Product Type, Value ($ mn) and Share (%)	32
Figure 10. Asia-Pacific Human Insulin Market: Human Insulin Drugs, 2019-2026, $ mn	33
Figure 11. Asia-Pacific Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, $ mn	34
Figure 12. Breakdown of Asia-Pacific Human Insulin Drugs Market by Product, 2019-2026, % of Revenue	35
Figure 13. Contribution to Asia-Pacific Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)	36
Figure 14. Asia-Pacific Human Insulin Market: Modern Human Insulin, 2019-2026, $ mn	37
Figure 15. Asia-Pacific Modern Human Insulin Market: Long-acting, 2019-2026, $ mn	39
Figure 16. Asia-Pacific Modern Human Insulin Market: Rapid- acting, 2019-2026, $ mn	40
Figure 17. Asia-Pacific Modern Human Insulin Market: Premixed, 2019-2026, $ mn	41
Figure 18. Asia-Pacific Modern Human Insulin Market: Lantus, 2019-2026, $ mn	42
Figure 19. Asia-Pacific Modern Human Insulin Market: Apidra, 2019-2026, $ mn	43
Figure 20. Asia-Pacific Modern Human Insulin Market: Levemir, 2019-2026, $ mn	44
Figure 21. Asia-Pacific Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, $ mn	45
Figure 22. Asia-Pacific Modern Human Insulin Market: Novomix, 2019-2026, $ mn	46
Figure 23. Asia-Pacific Modern Human Insulin Market: Humalog, 2019-2026, $ mn	47
Figure 24. Asia-Pacific Modern Human Insulin Market: Other Brands, 2019-2026, $ mn	48
Figure 25. Asia-Pacific Human Insulin Market: Traditional Human Insulin, 2019-2026, $ mn	49
Figure 26. Asia-Pacific Traditional Human Insulin Market: Short-acting, 2019-2026, $ mn	51
Figure 27. Asia-Pacific Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, $ mn	52
Figure 28. Asia-Pacific Traditional Human Insulin Market: Premixed, 2019-2026, $ mn	53
Figure 29. Asia-Pacific Traditional Human Insulin Market: Humulin, 2019-2026, $ mn	54
Figure 30. Asia-Pacific Traditional Human Insulin Market: Insuman, 2019-2026, $ mn	55
Figure 31. Asia-Pacific Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, $ mn	56
Figure 32. Breakdown of Asia-Pacific Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue	57
Figure 33. Contribution to Asia-Pacific Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)	58
Figure 34. Asia-Pacific Human Insulin Delivery Devices Market: Syringes, 2019-2026, $ mn	59
Figure 35. Asia-Pacific Human Insulin Delivery Devices Market: Pens, 2019-2026, $ mn	60
Figure 36. Asia-Pacific Human Insulin Delivery Devices Market: Pumps, 2019-2026, $ mn	61
Figure 37. Asia-Pacific Human Insulin Delivery Devices Market: Other Devices, 2019-2026, $ mn	63
Figure 38. Breakdown of Asia-Pacific Human Insulin Market by Application, 2019-2026, % of Revenue	64
Figure 39. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Application, Value ($ mn) and Share (%)	65
Figure 40. Asia-Pacific Human Insulin Market: Type 1 Diabetes, 2019-2026, $ mn	66
Figure 41. Asia-Pacific Human Insulin Market: Type 2 Diabetes, 2019-2026, $ mn	67
Figure 42. Asia-Pacific Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, $ mn	68
Figure 43. Breakdown of Asia-Pacific Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue	69
Figure 44. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)	70
Figure 45. Asia-Pacific Human Insulin Market: Hospital Pharmacies, 2019-2026, $ mn	71
Figure 46. Asia-Pacific Human Insulin Market: Retail Pharmacies, 2019-2026, $ mn	72
Figure 47. Asia-Pacific Human Insulin Market: Online Pharmacies, 2019-2026, $ mn	73
Figure 48. Breakdown of APAC Human Insulin Market by Country, 2019 and 2026, % of Revenue	75
Figure 49. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)	76
Figure 50.  Human Insulin Market in Japan, 2019-2026, $ mn	78
Figure 51.  Human Insulin Market in China, 2019-2026, $ mn	80
Figure 52.  Human Insulin Market in Australia, 2019-2026, $ mn	82
Figure 53.  Human Insulin Market in India, 2019-2026, $ mn	84
Figure 54.  Human Insulin Market in South Korea, 2019-2026, $ mn	86
Figure 55.  Human Insulin Market in Rest of APAC, 2019-2026, $ mn	88
Figure 56. Growth Stage of Asia-Pacific Human Insulin Industry over the Forecast Period	90
Astra Zeneca PLC	
Biocon	
Eli Lilly	
Exir	
Julphar	
Novo Nordisk AS	
Pfizer	
Sanofi Aventis	
Sedico	
Wockhardt